Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.
Lee S SchwartzbergGajanan BhatJulio PegueroRichy AgajanianJayaram S BharadwajAlvaro RestrepoOsama HlalahInderjit MehmiShanta ChawlaSteven J HasalZane YangPatrick Wayne CobbPublished in: The oncologist (2020)
Chemotherapy-induced neutropenia (CIN) remains a significant clinical dilemma for oncology patients who are striving to complete their prescribed chemotherapy regimen. In a randomized, phase III trial comparing eflapegrastim to pegfilgrastim in the prevention of CIN, the efficacy of eflapegrastim was noninferior to pegfilgrastim and had comparable safety. Nevertheless, the risk of CIN remains a great concern for patients undergoing chemotherapy, as the condition frequently results in chemotherapy delays, dose reductions, and treatment discontinuations.
Keyphrases
- chemotherapy induced
- phase iii
- open label
- clinical trial
- phase ii
- patients undergoing
- double blind
- placebo controlled
- end stage renal disease
- ejection fraction
- newly diagnosed
- palliative care
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- squamous cell carcinoma
- peripheral blood
- locally advanced
- patient reported outcomes
- combination therapy
- recombinant human